Subsense Emerges from Stealth with $17M to Develop Non-Surgical Brain-Computer Interface
What You Should Know: – Subsense, Inc., a pioneering neurotechnology company announced its official launch and the closing of a $17 million seed funding round led by Golden Falcon Capital. – The company is developing a groundbreaking non-surgical, nanoparticle-based Brain-Computer Interface (BCI) with the potential to transform the treatment of neurological conditions. Nanoparticle-Based Technology Aims ... Read More
What You Should Know:
– Subsense, Inc., a pioneering neurotechnology company announced its official launch and the closing of a $17 million seed funding round led by Golden Falcon Capital.
– The company is developing a groundbreaking non-surgical, nanoparticle-based Brain-Computer Interface (BCI) with the potential to transform the treatment of neurological conditions.
Nanoparticle-Based Technology Aims to Enhance Treatment of Neurological Conditions
Subsense is co-founded by Tetiana Aleksandrova, a neurotechnology entrepreneur with a passion for developing innovative solutions for brain health and Artem Sokolov, a serial entrepreneur and early investor in successful companies like Asana, SoFi, and Coursera.Subsense’s innovative technology utilizes nanoparticles to establish a bidirectional connection between the brain and external devices. This approach allows for targeted neural stimulation and precise monitoring, opening up new possibilities for treating a wide range of neurological disorders.
“Brain-computer interfacing promises to unlock limitless human potential, but innovation has been held back by a lack of effective non-surgical approaches,” said Tetiana Aleksandrova, Subsense’s Chief Executive Officer. “By delivering nanoparticles that bind with receptors in the brain, Subsense can achieve more extensive connectivity with a far gentler approach.”
Collaborating with Leading Research Institutions
Subsense is collaborating with a consortium of leading neurological research institutions, including UC Santa Cruz and ETH Zurich, to accelerate the development and validation of its technology.
Targeting Neurological Conditions
Subsense’s initial focus is on developing therapies for neurological conditions such as:
- Parkinson’s disease
- Alzheimer’s disease
- Epilepsy
- Depression
- Stroke
- Chronic pain
Expanding the Possibilities of Brain-Computer Interfaces
Beyond therapeutic applications, Subsense is also exploring more expansive possibilities for its technology, including:
- Sensorimotor recovery: Restoring vision, hearing, and movement.
- Inner speech decoding: Translating thoughts into words.
- AI integration: Merging the human brain with artificial neural networks.
- External memory: Creating a backup and extension of human memory.
- Mental health regulation: Monitoring and controlling emotions and mood.
- Appetite control: Managing hunger and satiety signals.
